Skip to main content
Black Diamond Therapeutics, Inc. (BDTX)
NASDAQ: BDTX · Real-Time Price · USD
1.620
+0.025 (1.57%)
Nov 11, 2026, 12:24 PM EST - Market open

BDTX Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
-70----
Revenue Growth
------
Gross Profit
-70----
Selling, General & Admin
18.0316.5727.4727.1128.3930.04
Research & Development
27.6733.5651.3159.3564.4496.83
Operating Expenses
45.750.1378.7886.4692.83126.87
Operating Income
-45.719.87-78.78-86.46-92.83-126.87
Interest & Investment Income
3.964.062.181.922.033.46
Earnings From Equity Investments
-----2.25-
Currency Exchange Gain (Loss)
------0
Other Non Operating Income (Expenses)
3.744.513.140.920.18-
EBT Excluding Unusual Items
-3828.44-73.46-83.62-92.87-123.41
Gain (Loss) on Sale of Investments
1.281.283.781.17-0.54-2.19
Gain (Loss) on Sale of Assets
----2.23-
Asset Writedown
-7.35-7.35----
Pretax Income
-44.0722.37-69.68-82.44-91.17-125.6
Net Income
-44.0722.37-69.68-82.44-91.17-125.6
Net Income to Common
-44.0722.37-69.68-82.44-91.17-125.6
Net Income Growth
------
Shares Outstanding (Basic)
575755443636
Shares Outstanding (Diluted)
575855443636
Shares Change
0.03%4.61%25.19%21.00%0.38%9.97%
EPS (Basic)
-0.770.39-1.27-1.88-2.51-3.47
EPS (Diluted)
-0.770.39-1.27-1.88-2.51-3.47
EPS Growth
------

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
-33.3329.61-62.3-66.75-85.27-102.86
Free Cash Flow Per Share
-0.580.51-1.13-1.52-2.35-2.84
Gross Margin
-100.00%----
Operating Margin
-28.39%----
Profit Margin
-31.95%----
Free Cash Flow Margin
-42.31%----
EBITDA
-45.5520.2-78.44-86.02-92.32-126.67
EBITDA Margin
-28.85%----
D&A For EBITDA
0.150.330.340.440.510.21
EBIT
-45.719.87-78.78-86.46-92.83-126.87
EBIT Margin
-28.39%----
SEC Filings: 10-K · 10-Q